Halozyme Therapeutics, Inc. vs. Kymera Therapeutics, Inc. Common Stock
HALO
Halozyme Therapeutics, Inc.
$100.67 -1.10%
VS KYMRKymera Therapeutics, Inc. Common Stock
$117.39 +2.60%
Halozyme Therapeutics, Inc. (HALO) comes out ahead, leading on 6 of 8 compared factors.
Size & Scale
| HALO | KYMR | |
|---|---|---|
| Market Cap | $11.55 billion | $9.48 billion |
| Revenue (TTM) | $1.66 billion | $105.00 million |
| Net Income (TTM) | $413.60 million | $-299,601,000 |
HALO leads on 3 of 3 size & scale factors.
Valuation
| HALO | KYMR | |
|---|---|---|
| P/E Ratio | 29.35 | — |
| Price / Book | 80.48 | 6.28 |
| Price / Sales | 6.94 | 90.30 |
HALO and KYMR split the valuation factors evenly.
Profitability
| HALO | KYMR | |
|---|---|---|
| Net Margin | 24.86% | -285.34% |
| Return on Equity | 288.13% | -19.85% |
HALO leads on 2 of 2 profitability factors.
Risk & Sentiment
| HALO | KYMR | |
|---|---|---|
| Short Interest | 9.79% | 0.24% |
KYMR leads on 1 of 1 risk & sentiment factors.
Dig deeper: HALO overview, HALO financials, KYMR overview, KYMR financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.